Today breast cancer has become one of the most common cancers in the world. Chalcones and urea cores are widely studied in biomedical research because of their many important biological activities. These cores have been employed in drug discovery to search new cancer treatments and overcome drug resistance. Ferrocene is an organometallic compound that has been incorporated as a bioisostere to a variety of well-known active scaffolds and has improved their bioactivity, including FDA clinical trials drugs Ferrocifen and Tamoxifen. Replacing an aromatic ring with ferrocene in chalcones has proven to enhance their anticancer properties. Moreover, other bioactive groups as diphenyl urea can be incorporated in the ferrocenyl-chalcones core and exhibit a synergistic effect that enhance their independent biological potential. Diphenyl urea has activity on Activity on Vascular Endothelial Growth Factor Receptors (VEGFRs), on Epidermal Growth Factor Receptors (EGFRs), and other factors that made it a potential antitumorigenic agent. Therefore, our hypothesis states that a hybrid scaffold of ferrocenyl chalcones and diphenyl urea will lead promising antitumorigenic agents. This research work aims to synthetized ferrocenyl-urea-chalcones derivatives by a three steps synthesis, characterization, and to study their anticancer activity in MCF-7 and MDA-MB-231 breast cancer cell lines. The compounds were successfully synthetized in moderate to good yields and characterized using FT-IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR. The methodology, characterization, bioactivity, and future work will be elaborated.

Synthesis of ferrocenyl-urea-chalcones: potential hybrids antitumorigenic agents

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.